Adam Schechter

Global business leader Adam Schechter became Chief Executive Officer of Labcorp in November 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director in January 2019 after serving as a director of the company since 2013.

Developments in cardiometabolic care for the primary care physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.

Society for Immunotherapy of Cancer (SITC 2024)

Antibody-drug conjugate (ADC): Navigating complex cancer therapy development

Support with developing an ADC targeted chemotherapy and CDx enabled a sponsor to navigate therapy complexity, global trial design and patient selection for a breakthrough cancer treatment.

nAbCyte™ CDx: One-time treatment. Zero room for error.

An estimated 6,000 people  in the United States live with hemophilia B. nAbCyte—the first cell-based CDx for gene therapy—offers new hope in delivering the right treatment to the right patients.

pTau217: Providing critical Alzheimer's diagnosis with key biomarker data

Every 3.2 seconds, someone globally is diagnosed with Alzheimer’s. pTau217—Labcorp’s simple and highly accurate blood-based test—offers clear answers to accelerate new, needed therapies.

Early phase development solutions: Accelerating answers for a global pandemic

A quick response to the COVID-19 pandemic helped a sponsor reduce their IND program from 12 to 5 months. With Labcorp Phase I and II trial work support, the sponsor achieved FDA emergency use authorization.

Personalized Medicine Coalition Conference​ (PMC 2024)

Antibody-drug conjugate bioanalysis: A case study in stability, matrix effects and recovery

APA 2024 -- Antibody-drug conjugates (ADCs) are an increasingly popular approach to selectively deliver a drug, the “payload”, to target cells or tissues with minimal off-target effects. A proprietary ADC with a self-immolative linker is being investigated. Three bioanalytical assays in nonhuman primate (NHP) plasma are to be developed: Total antibody, free payload and conjugated payload.